Additionally, in August 2022, the FDA granted accelerated approval to trastuzumab-deruxtecan (T-DXd) antibody-drug conjugate (ADC) based on impressive DESTINY-Lung02 trial results, making it the first approved targeted therapy for HER2-mutant NSCLC (13). Here, ERBB2 is linked to non-small cell lung carcinoma.